TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plasma Presepsin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum gelsolin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR corrected clinical and parasitological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) and recommended phase 2 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of intravitreal aflibercept injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum absorption rate of drink
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for D2O
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent reduction in LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune-related Progression Free Survival (irPFS) at 20 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Immune-related Objective Response Rate
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (PFS) at 20 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: number of gastrointestinal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Insulin-independent Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Knee Documentation Committee Subjective Knee Evaluation Form (IKDC Score) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kellgren-Lawrence (K/L) grade change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of PF-05221304
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-05221304
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction Unbound (fu) of PF-05221304
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of adverse events during the study
Endpoint domain: Adverse events/effects
Primary endpoint: Subject withdrawals due to treatment-emergent adverse events
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Plasma Concentration (Cmax) of Simeprevir (SMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Plasma Concentration (Tmax) of SMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From 0 to last (AUC[0-last]) Post Dose of SMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of neurological disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to healing of foot ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung health and asthma measured by Brief Respiratory Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung health and asthma measured by PROMIS Parent Proxy Asthma Impact item bank
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lung health and asthma measured by spirometry and bronchodilator responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline-adjusted Area Under Effect Curve (AUEC) for LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Change From Baseline for LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Virologically-confirmed dengue (VCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Best spectacle corrected visual acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virologic response at 12 weeks after the end of intervention (SVR-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of local and general adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: sims score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Carer quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Preferring Tadalafil Over Sildenafil
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of solicited injection site and systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of study vaccine-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of clinical safety laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in objectively measured exercise behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage change of the BMD parameters from baseline BMD values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage change of bone biomarker measurements (serum bone alkaline phosphatase and urine N-telopeptide) from baseline values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients with postoperative pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with productive cough and difficult expectoration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with hoarseness
Endpoint domain: Adverse events/effects
Primary endpoint: GVHD assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Improvement, Disease Progression or Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Agreement between LINQ and capnography derived respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of stoma in each group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severe health events (grade 3-4)
Endpoint domain: Adverse events/effects
Primary endpoint: Ophthalmological events
Endpoint domain: Adverse events/effects
Primary endpoint: Immunological events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cytokine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in bacterial species measured in fecal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Histologic measures of tumor fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: motor Functional Independence Measure (mFIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Montebello Rehabilitation Factor Score (MRFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole body fat quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of CO readings completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Histopathological scoring of vascular density, apoptotic and mitotic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FDG-PET response of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of OC/tic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18-item total ADHD symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with expected pre dose concentration of lopinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Time to Discontinuation for Any Reason
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Variation of conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from preoperative maximum knee flexion during swing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of PICC-RVT
Endpoint domain: Adverse events/effects
Primary endpoint: quantitative change in plasma amino acids at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Distance Visual Acuity (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite outcome of non-fatal venous thromboembolism (VTE), non-fatal major hemorrhage, INR>=4.0, and death
Endpoint domain: Mortality/survival
Primary endpoint: composite outcome of non-fatal venous thromboembolism (VTE) and death
Endpoint domain: Mortality/survival
Primary endpoint: Dose and irradiated volume of small bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dose and irradiated volume of urinary bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of serotypes with a response (doubling in antibody titer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in diet quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in food insecurity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in uterine tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to adequate uterine tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total calculated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Naming Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of NAFLD and NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in anthropometric indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL and HDL Cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ovary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pain and disability in the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in Worst Ocular Itching Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of urinary NTx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pressure Pain Detection Threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal Summation Pain (TS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain with cervical dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary artery pulse doppler flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: t½ (half-life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of life assessed by EORTC-QLQ C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Depression and anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Upper Limb Fugl Meyer Scale (ULFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood parameters related to Non ST elevated MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: adjusted horizontal reading time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Q-LES-Q score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Flap thickness accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of tumor markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Interval from first misoprostol dose to vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of women who delivered infants vaginally within 12 and 24 hours of induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of tachysystole, hypertonus, uterine hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Resting state parameters of fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline of Short Physical Performance Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to LCS Guidelines and CMS Coverage Criteria
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change In Lactate Dehydrogenase Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of zanubrutinib (AUC(0-24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of zanubrutinib (AUC(0-∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of zanubrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unused opioids
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cortisol cut offs for normal response to Synacthen®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of dental plaque accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in speech outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Symptomatic resolution of UTI-specific symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological eradication and symptomatic resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of protamine/heparin antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of having a composite adverse birth outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of any grade 3-4 Adverse Events (AE) or Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Event free survival for the whole cohort
Endpoint domain: Mortality/survival
Primary endpoint: Event free survival for patients in High risk group
Endpoint domain: Mortality/survival
Primary endpoint: sensitive electrophysiological index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite outcome including adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cost per prevented child with serious illness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intraperitoneal Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: 1st trimester pregnancy loss
Endpoint domain: Mortality/survival
Primary endpoint: Medical Outcomes Study HIV Health Survey (MOS-HIV) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression Free Rate (PFR)
Endpoint domain: Mortality/survival
Primary endpoint: Time to first formed or hard stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Net MACCE
Endpoint domain: Mortality/survival
Primary endpoint: Change in HSCL-11 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Fasting sBA Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual analogue scale (VAS) rating for pain intensity and unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of order sessions with RAR events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: new colorectal liver metastases detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Barriers to completing recommended at home self-care of lymphedema
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Patients recalled instructions for at home self-care practices for lymphedema
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Current at home self-care practices for lymphedema
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Transdermal fentanyl drug delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate of AG-013736
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of treatment-emergent laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: afferent cortical evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in serum total cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of anxiety disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in raltegravir Area under the curve (AUC)0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of IMRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Daily Normalized On Time Without Troublesome Dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of Life - WHOQOL-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life - WHOQOL-OLD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depression, Anxiety and Stress - Dass 21
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Required Study Drug Dose Reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Relative 16S Abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in genomic DNA of Candida sp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VAS determination of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Biomarkers of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: anti-Polio antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma concentration of mepivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulation of Paramagnetic Rim Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With the Complement 3a (C3a) Unit Predominating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain Scores on the FLACC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hot flush score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombin Generation Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes